When does ABIONYX report earnings and how could it move ABNX.PA stock?

ABIONYX reports on **12 Mar 2026**. The result and management commentary on cash runway or CER-001 timelines can trigger high volatility in ABNX.PA stock, given its development-stage valuation and thin liquidity.

What is Meyka AI's price forecast for ABNX.PA stock?

Meyka AI's forecast model projects a yearly target of **EUR 5.87**. Versus the current **EUR 3.46**, this implies about **69.62%** upside. Forecasts are model-based projections and not guarantees.

What are the main valuation risks for ABNX.PA stock?

Valuation risks include negative EPS **-0.13**, high price/sales **26.35**, and price/book **20.94**. These metrics mean the stock prices in successful clinical outcomes, increasing downside if trials disappoint.

How should traders manage position risk around ABNX.PA earnings?

Given ATR **EUR 0.16** and thin average volume, limit position size, set stop levels near **EUR 3.00** support, and avoid full exposure into the print. Consider options or scaled entries to manage binary event risk.

EU Stocks

ABNX.PA ABIONYX Pharma EURONEXT +5.01% intraday 10 Mar 2026 ahead of earnings: watch CER-001

ByHuzaifa Zahoor March 10, 2026March 10, 2026

ABNX.PA stock jumped 5.01% intraday to EUR 3.46 on 10 Mar 2026 as investors position ahead of ABIONYX Pharma SA’s earnings scheduled for 12 Mar 2026. We see trading activity lift volume to 127,136.00 shares versus a 30‑day average of 153,900.00. The short-term move reflects focus on clinical readouts for CER-001 and liquidity sensitivity in small-cap biotech names on EURONEXT.